Zobrazeno 1 - 10
of 35
pro vyhledávání: '"M. A. Espeland"'
Autor:
A. S. Carew, R. A. Warren, M. P. Bancks, M. A. Espeland, J. L. Bahnson, C. L. Lewis, A. P. Levy, J. L. Sapp, R. Urquhart, J. L. Wang, E. B. Rimm, L. E. Cahill
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-14 (2024)
Abstract Background In the ACCORD study, participants with the haptoglobin (Hp) 2–2 phenotype and glycated hemoglobin (HbA1c) ≥ 8.0% had a higher risk of coronary artery disease (CAD) compared to those with HbA1c 7.0–7.9%. However, this associa
Externí odkaz:
https://doaj.org/article/2bbd6ead508e43af963be028109a7b00
Autor:
J. Rushing, R. Wing, T. A. Wadden, W. C. Knowler, M. Lawlor, M. Evans, T. Killean, M. Montez, M. A. Espeland, P. Zhang, The Look AHEAD Research Group
Publikováno v:
Obesity Science & Practice, Vol 3, Iss 1, Pp 15-24 (2017)
Summary Objective The Action for Health in Diabetes (Look AHEAD) trial was a randomized controlled clinical trial to compare the effects of 10 years of intensive lifestyle intervention (ILI) with a control condition of diabetes support and education
Externí odkaz:
https://doaj.org/article/e85fe9cf02d54ad782f17d45a950ab32
Autor:
A P Pandey, K V P Patel, M S K Khan, J L B Bahnson, K R G Garcia, J M C Clark, A B Balasubramanyam, A G B Bertoni, M V Vaduganathan, M E F Farkouh, J L J Januzzi Jr, S V Verma, M E Espeland
Publikováno v:
European Heart Journal. 43
Background Type 2 diabetes (T2D) is characterized by co-morbid cardiometabolic abnormalities and elevated heart failure (HF) risk. Purpose The purpose of this study was to evaluate the associations of baseline and longitudinal changes in cardiometabo
ENRGISE screening began in March 2016. Of those who responded to the recruitment efforts, 83% responded to mass mailings. Of the 5424 telephone screens completed, 2011 (37%) were eligible for further screening. Of the 1305 initial screening visits (S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39085b7922564d5f8f9ca4092c44ea29
https://europepmc.org/articles/PMC6226938/
https://europepmc.org/articles/PMC6226938/
Autor:
M. A. Espeland
Publikováno v:
Journal of Clinical Endocrinology & Metabolism. 82:1549-1556
Autor:
M, Haan, M A, Espeland, B E, Klein, R, Casanova, S A, Gaussoin, R D, Jackson, A E, Millen, S M, Resnick, J E, Rossouw, S A, Shumaker, R, Wallace, K, Yaffe, Linda, Pottern
Publikováno v:
Neurology. 78(13)
Objective: To examine the association between retinopathy and cognitive decline or brain lesions and volumes in older women. Methods: This study included 511 women aged 65 and older who were simultaneously enrolled in the Women9s Health Initiative Me
Publikováno v:
Journal of the American Society of Nephrology. 3:1467-1473
Black patients with insulin-dependent diabetes mellitus are at increased risk for the development of diabetic nephropathy compared with white patients. To determine if genetic differences associated with the HLA system account for racial variation in
Autor:
M A Espeland
Publikováno v:
Gesundheitsökonomie & Qualitätsmanagement. 20:8-8
Autor:
R P, Byington, G W, Evans, M A, Espeland, W B, Applegate, D B, Hunninghake, J, Probstfield, C D, Furberg
Publikováno v:
Circulation. 100(3)
Few clinical trials have documented the efficacy of preventive treatment in asymptomatic women.Lovastatin and minidose warfarin were evaluated in a factorially designed, placebo-controlled, randomized trial. The primary outcome was 3-year change in t
Autor:
M A, Espeland, P K, Whelton, J B, Kostis, J L, Bahnson, W H, Ettinger, J A, Cutler, L J, Appel, S, Kumanyika, D, Farmer, J, Elam, A C, Wilson, W B, Applegate
Publikováno v:
Archives of family medicine. 8(3)
National guidelines recommend consideration of step down or withdrawal of medication in patients with well-controlled hypertension, but knowledge of factors that predict or mediate success in achieving this goal is limited.To identify patient charact